Kura Oncology Narrows Loss And Beats As KOMZIFTI Launch Builds, But Collaboration Cut, Dilution, And Debt Shape A Battered Stock's Setup

Kura Oncology delivered the quarter it needed. Whether the market rewards it is another matter. The company reported a third-quarter loss of $0.78 per share, ahead of the -$0.83 consensus for a 6.0% surprise, and an 8.2% year-over-year improvement in earnings as the net loss narrowed to $70.2 million from $74.1 million. Revenue of $22.84 million topped the $22.2 million estimate by 2.9% and grew 10.1% from a year ago. The modest total-revenue growth understates the real development. KOMZIFTI net product revenue rose 53% sequentially to $13.9 million, more than offsetting a sharp drop in Kyowa Kirin collaboration revenue to $8.9 million from $20.8 million a year earlier. The revenue base is shifting from partner accounting to product sales. That is the central story of the quarter.

The quality of the beat holds up better than in many early-launch biotech quarters. KOMZIFTI has climbed from $2.1 million in the fourth quarter of 2025 to $5.8 million, $9.1 million, and now $13.9 million. Sequential dollar additions are still widening, even as percentage growth settles into the low-50s. Expense discipline also contributed. R&D slipped to $66.9 million from $67.9 million, and SG&A fell to $30.2 million from $32.8 million, despite a full commercial launch. The narrower loss reflects real operating progress rather than a one-time item.

The call added depth to the launch picture:

• **Patient starts:** New patient starts rose to roughly 150 from about 115 in the second quarter and 85 in the first.
• **Prescriptions:** Total prescriptions jumped 65% to more than 420. That gap with new starts points to a growing refill contribution.
• **Accounts:** Prescribing accounts reached 170, up 40% sequentially and from roughly 60 in the first quarter.
• **Combination use:** Combination use rose to nearly half of new starts from about 40%.
• **Coverage:** Covered lives are now near 100%.
• **Market share:** KOMZIFTI kept a majority of menin-inhibitor new patient starts in relapsed/refractory NPM1-mutated AML.

There are softer edges. New-start growth eased slightly from roughly 35% to 30%. Analysts also pressed on whether prescriptions and revenue are running below what a roughly five-month duration of therapy would imply. Management's description of the frontline KOMET-017 program also shifted from "ahead of plan" earlier in the year to "on track."

The forward catalysts are substantive:

• **Darlifarnib:** FDA alignment on an approximately 40-patient single-arm registrational study in HRAS-mutant salivary gland cancer gives Kura a relatively lean path to a potential second approval, with initiation targeted for the first half of 2027.
• **ASH data:** Eight ziftomenib abstracts are slated for ASH, including the first FLT3-inhibitor combination data with quizartinib and gilteritinib and pediatric data that include patients previously exposed to revumenib.
• **Later milestones:** Renal cell data are expected in the second half of 2027, and KOMET-017 topline results in 2028.

Against that, bears have legitimate ammunition:

• **Guidance cut:** Kura trimmed 2026 collaboration revenue guidance to $40 million to $45 million from $45 million to $55 million. It is non-cash accounting, but it is still a cut. Guidance for 2027 and 2028 was held at $90 million to $110 million.
• **Competition:** A third menin inhibitor from J&J is emerging as a competitive overhang.
• **Financing costs:** The Oberland Capital deal provides up to $300 million, with $55 million received at closing. It carries 6.95% to 8.95% interest and a capped single-digit royalty on U.S. KOMZIFTI sales.
• **Dilution:** Roughly $32 million was raised through the at-the-market program, and a renewed $150 million ATM keeps dilution on the table.

The balance sheet explains why the financing mattered. Cash fell to $492.1 million from $667.2 million at year-end. Stockholders' equity dropped to just $18.0 million from $174.1 million. Management now says resources, including an anticipated $180 million in Kyowa Kirin milestones, fund the full operating plan beyond the 2028 KOMET-017 readout. On prior calls, that runway covered the AML program only. The extension is a genuine de-risking, but it was bought with leverage and royalty obligations.

The market setup is more complicated than the surprise implies. Shares entered the report at $7.57, down 28.6% from the $10.60 open after the August release. The stock is 22.6% below its 200-day moving average of $9.78. It traveled from a 52-week high of $13.90 on August 25 to a 52-week low of $6.75 on November 6, both within this quarter, and sits only about 12% above that low. Investor sentiment nonetheless became more positive, rising from 0.18 to 0.29. That is a meaningful but not dramatic improvement, suggesting expectations were firming even as the price slid. The Earnings Whispers trend readings reflect that split. Sequential growth and momentum are positive, while price and AVWAP trends remain negative.

The bottom line is that Kura's commercial execution is improving on nearly every operating metric, and the financing removes near-term funding anxiety through its most important clinical readout. The stock's steep slide, however, shows investors are discounting competitive pressure, launch-trajectory math, and the cost of capital. Continued sequential KOMZIFTI growth and a well-received ASH showing are the clearest paths to narrowing that gap.

Read our earnings preview for Kura Oncology, Inc.: https://www.earningswhispers.com/article/KURA/22802

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.